Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Revenue (2016 - 2022)

Aptevo Therapeutics' Revenue history spans 8 years, with the latest figure at $3.1 million for Q1 2022.

  • For Q1 2022, Revenue rose 28.62% year-over-year to $3.1 million; the TTM value through Dec 2022 reached $3.1 million, down 74.67%, while the annual FY2022 figure was $3.1 million, 74.67% down from the prior year.
  • Revenue for Q1 2022 was $3.1 million at Aptevo Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Revenue topped out at $9.0 million in Q4 2019 and bottomed at $473000.0 in Q2 2020.
  • The 5-year median for Revenue is $3.7 million (2021), against an average of $4.6 million.
  • The largest annual shift saw Revenue tumbled 93.57% in 2020 before it soared 557.51% in 2021.
  • A 5-year view of Revenue shows it stood at $5.8 million in 2018, then skyrocketed by 55.07% to $9.0 million in 2019, then tumbled by 73.72% to $2.4 million in 2020, then surged by 54.45% to $3.7 million in 2021, then fell by 15.03% to $3.1 million in 2022.
  • Per Business Quant, the three most recent readings for APVO's Revenue are $3.1 million (Q1 2022), $3.7 million (Q4 2021), and $3.1 million (Q3 2021).